title: Use of177Lu-dotatate in the treatment of iodine refractory thyroid carcinomas.
abstract: In a patient with a differentiated thyroid cancer the standard treatment protocol to be followed is surgery, ablation of thyroid remnants with131Iodine (131I), and TSH suppression. However, the treatment with131I is not effective in some cases, and it no longer becomes a therapeutic option due to cell de-differentiation with loss of131I uptake. Systemic treatment can be used as other options, although patients are not always responsive; thus, the disease may progress and therapeutic options may run out. Endocrine tumours may express somatostatin receptors,and this characteristic has been used, not only for diagnosis, but also for their treatment through somatostatin analogue labelling with radioactive isotopes. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin receptors expression, treated with177Lu-DOTATATE, showing an excellent clinical and analytical response.
authors: Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España. Electronic address: polivansasot@hotmail.com.
authors: P
authors: P
authors: Oliván-Sasot
authors: Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España.
authors: M
authors: M
authors: Falgás-Lacueva
authors: Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, España.
authors: J
authors: J
authors: García-Sánchez
authors: Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España.
authors: V
authors: V
authors: Vera-Pinto
authors: Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España.
authors: C
authors: C
authors: Olivas-Arroyo
authors: Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España.
authors: P
authors: P
authors: Bello-Arques
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006044:Goiter, Nodular / Q000150:complications / Q000601:surgery; D006801:Humans; D007191:Indazoles; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary*; D008187:Lutetium / Q000627:therapeutic use*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010166:Palliative Care; D010671:Phenylurea Compounds / Q000627:therapeutic use; D000072078:Positron Emission Tomography Computed Tomography; D011743:Pyrimidines / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D000077157:Sorafenib; D013449:Sulfonamides / Q000627:therapeutic use; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D007191:Indazoles; D007457:Iodine Radioisotopes; D009942:Organometallic Compounds; D010671:Phenylurea Compounds; D011743:Pyrimidines; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013449:Sulfonamides; D009536:Niacinamide; D008187:Lutetium; C516667:pazopanib; D004317:Doxorubicin; D013954:Thyroglobulin; D000068338:Everolimus; D000077157:Sorafenib; C447941:lutetium Lu 177 dotatate; C000615061:Lutetium-177; D015282:Octreotide
keywords: (177)Lu-DOTATATE; Cáncer de tiroides; Peptide receptor radionuclide Therapy; Radioactive iodine refractory; Refractario al yodo radiactivo; Thyroid neoplasms; Tratamiento con análogos de la somatostatina radiomarcados